Inclisiran launch?

When was inclisiran launched?

Inclisiran (marketed as Leqvio) launched in the European Union in 2020, after approval by the European Medicines Agency (EMA) for reducing low-density lipoprotein cholesterol (LDL-C) in adults at elevated cardiovascular risk or with established cardiovascular disease. [1]

Who markets inclisiran (Leqvio) and where is it available?

Leqvio is marketed by Novartis in major markets, starting with European launch following EMA approval in 2020. [1]

Why did clinicians look for inclisiran around its launch?

Inclisiran is a long-acting cholesterol-lowering therapy designed for less frequent dosing than daily statins. That dosing convenience is one reason payers and prescribers tracked its rollout closely once it reached market.

What to check next: pricing, coverage, and patent timeline

If you’re researching launch impact, competitive positioning, or long-term market protection (patents/exclusivity), DrugPatentWatch.com tracks patent and exclusivity information for drugs like inclisiran/Leqvio. [2]

Sources

[1] https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio
[2] https://www.drugpatentwatch.com/